Portfolio

Financial Services Technology Healthcare Energy

TearLab Corporation

NASDAQ:TEAR, TSX:TLB

TearLab Corporation, headquartered in San Diego, California, is commercializing a proprietary in vitro diagnostic tear testing platform, TearLab?, capable of accurately and rapidly measuring biomarkers in tears at the point-of-care.

TearLab Corporation is developing TearLab? Osmolarity, a test intended to measure tear film osmolarity.

TearLab Corporation completed a merger with Occulogix Inc. in 2008. Occulogix Inc. went public in 2004 raising over 100 Million dollars to support its commercialization efforts.


MacuHealth

Macular Degeneration is a degenerative eye disease and the leading cause of blindness in people over the age of 50 in North America. Low Macular Pigment (MP) is a major risk factor for Macular Degeneration.

Macuhealth with LMZ3 is a patented nutritional supplement that contains the three pigments found in the macula. Regular intake of Macuhealth with LMZ3 has been shown to restore macular pigment to normal levels (up to 40% increase in MP over a 6 month period*)

The MacuScope™ is an instrument that can accurately measure MP and is essential in screening low MP patients as well as tracking ongoing restoration of MP to normal levels.


ScienceWithVision Inc.

ScienceWithVision Inc. is a Canadian medical technology organization that is focused on providing eye doctors with state-of-the-art medical technology to raise their standard of care options.

ScienceWithVision is the exclusive Canadian distributor for the Health Canada approved MacuScope™ – Canada’s first macular pigment optical density meter. This instrument allows eye doctors to identify patients at risk for Macular Degeneration and we provide sales, leasing and support for clinics across Canada. Our MacuHealth with LMZł supplement is a patented formulation including only the three retinal carotenoids found in the macula and is designed to re-pigment the macula and reduce patients’ risk for AMD. MacuHealth with LMZł has shown up to 40% increase in Macular Pigment over 6 months* and is available only through eye doctors.

Our Management and Medical Advisory teams are industry leaders in eye care technology and are dedicated to providing the newest and most effective technologies to eye doctors across Canada.

Home | Contact © 2009 Greybrook Capital